[email protected]

Category: Pharma Audits

GMP Mock Inspection

Pharma Audits

GMP Mock Inspection for Pharmaceutical Manufacturers: What Global Regulators Check That Internal Teams Miss

May 21, 2026 No Comments

Regulatory Deficiency

GVP Audits

How to Respond to a Regulatory Deficiency Letter: A Step-by-Step CAPA Guide for Pharmaceutical Sites

May 19, 2026 No Comments

DARWIN EU Real-World Evidence

Pharma Audits

DARWIN EU Real-World Evidence: How Drug Safety Consulting Services Use 250 Million Patient Records

April 28, 2026 No Comments

Before Your QA Meeting

Pharma Audits

Before Your QA Meeting: 10 Quality Signals Every Leader Should Track

April 23, 2026 No Comments

Evidence Collection Flaws That Trigger

GVP Audits

Evidence Collection Flaws That Trigger Escalated Observations in Hybrid Audits

April 21, 2026 No Comments

Visual Inspection 4.0

Pharma Audits

Visual Inspection 4.0: Machines That Never Miss a Defect (And Regulators Love It)

April 16, 2026 No Comments

Annex 15 Revision

Pharma Audits

Annex 15 Revision: Key Impacts on Qualification and Validation for GDP Operators

March 31, 2026 No Comments

EU Pharma Package

Pharma Audits

EU Pharma Package 2026: What It Means for GMP/GDP Operators Now

March 19, 2026 No Comments

Pharma Audits

Pharma Audits

Third‑Party PV Subcontractors in the Crosshairs: How to Audit‑Proof Your Vendor Agreements

March 10, 2026 No Comments

FDA Warning Letter support

Pharma Audits

Why 87% of FDA Warning Letters Require External GMP Consultants

February 12, 2026 No Comments

Let’s build a GxP-compliant future together.

Have a project in mind?

Partner with us to elevate your quality systems, ensure compliance, and drive meaningful business transformation.

Built with passion and purpose. Helping you grow smarter, not harder.

QUICK LINKS

CONTACT US

[email protected]

Newsletter Signup

Subscribe to our newsletter for the latest insights

Copyright © 2026 Quality Vigilance Ltd | All Rights Reserved || Powered by Prabisha Consulting